Analysts expect ESSA Pharma Inc. (NASDAQ:EPIX) to report $-0.43 EPS on December, 10.They anticipate $1.37 EPS change or 76.11 % from last quarter’s $-1.8 EPS. After having $-0.50 EPS previously, ESSA Pharma Inc.’s analysts see -14.00 % EPS growth. The stock decreased 2.99% or $0.1 during the last trading session, reaching $3.24. About 73 shares traded. ESSA Pharma Inc. (NASDAQ:EPIX) has declined 49.84% since November 14, 2017 and is downtrending. It has underperformed by 65.46% the S&P500.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $23.50 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.
Another recent and important ESSA Pharma Inc. (NASDAQ:EPIX) news was published by Nasdaq.com which published an article titled: “Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and …” on November 14, 2018.